Enrique Grande: Poor Outcomes for Basal/Squamous and Mixed Bladder Cancers in the VESPER Trial

Enrique Grande shared the following on LinkedIn:

“Basal/squamous and Mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial.”

Basal/squamous and Mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial

Authors: C.S. Groeneveld, C. Pfister, S. Culine, V. Harter, C. Krucker, J. Fontugne, V. Dixon, N. Sirab, I. Bernard-Pierrot, A. de Reyniès, F. Radvanyi, Y. Allory, VESPER trial investigators.

Source: Enrique Grande/LinkedIn

Enrique Grande, MD, PhD, MSc, is an Associate Professor at Francisco de Vitoria University. He is also an Adjunct Professor at the GU Medical Oncology Department and the Head of Oncology at MD Anderson Cancer Center. Grande specializes in researching genitourinary and endocrine tumors and actively collaborates in developing the Translational Research and Early Drug Development Unit. He founded the Spanish Group for Research on Orphan and Uncommon Tumors (GETHI) and serves on the Directory Board of the Spanish Task Force Group for NETs (GETNE). Dr. Grande edits several international journals and has participated in recent neuroendocrine tumor trials that led to the approval of new drugs in this field.